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Background: Local recurrence (LR) after breast-conservation therapy for breast cancer
occurs in 10% to 15% of cases. A subset of these represents biologically aggressive disease, yet
prognostic features for identifying this high-risk category are lacking. We hypothesized that
lymphatic mapping and sentinel lymph node biopsy would provide useful information
regarding dominant lymphatic drainage patterns of patients with LR.
Methods: Breast cancer case records involving surgery for LR at the University of Michigan
from 2002 to 2004 were reviewed. The lymphatic drainage patterns were compared with those
of 117 patients who underwent mapping for primary breast cancer.
Results: Fourteen LR cases were identified (10 with initial axillary lymph node dissection, 2
with initial sentinel lymph nodes, and 2 with no axillary surgery at the time of primary cancer
treatment); lymphatic mapping was performed in 10. The sentinel lymph node identification
rate was 90%, the median number of lymph nodes retrieved was 3, and no metastases were
detected. Significantly more cases of nonipsilateral axillary sentinel node drainage were ob-
served in mapping procedures performed for LR compared with those for primary breast
cancer (67% vs. 15%; P = .001).
Conclusions: Lymphatic mapping is feasible in patients undergoing mastectomy for LR and
is likely to identify aberrantly located sentinel lymph nodes that would otherwise be over-
looked with a conventional completion mastectomy.
Key Words: Breast cancer—Local recurrence—Sentinel lymph node—Breast-conservation
therapy.
Breast cancer incidence rates continue to increase
among American women; however, earlier detection
of disease with screening mammography, coupled
with advances in breast cancer treatment, is resulting
in overall outcome improvements and decreased
mortality rates.1 These trends will result in larger
numbers of patients treated by breast-conservation
therapy (consisting of lumpectomy and adjuvant
breast radiotherapy), and the preserved breast is an
ongoing source for additional neoplastic events in the
form of true local recurrence or new primary tumors.
Salvage mastectomy is the standard of care for local
control in these cases, with 5-year survival rates
averaging 60% to 75%.2–7 The prognosis for patients
with recurrent disease in the breast has been corre-
lated with the disease-free interval, the size of the
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recurrence, and the status of the regional
lymph nodes.3,4,8–11 Nodal staging of the axilla is
compromised in patients who have previously
undergone a standard level I/II axillary lymph node
dissection (ALND). Furthermore, primary lymphatic
drainage patterns are likely to have been diverted
toward nonaxillary nodal basins as a consequence of
the prior ALND, as well as the adjuvant breast
radiotherapy. This has been demonstrated to a lim-
ited extended in some studies with small sample si-
zes.12 Identification of aberrant lymphatic drainage
pathways also helps to explain the pathogenesis of
unusual patterns of breast cancer failure, such as
contralateral axillary metastases.13
Determining the systemic adjuvant therapy needs
in locally recurrent breast cancer is challenging. Most
local recurrences will be successfully treated by sal-
vage mastectomy alone. A subset of these cases,
however, will represent biologically more aggressive
breast cancers for which systemic therapy is war-
ranted, but currently available imaging studies are
inadequate for identifying these patients.14 Identifi-
cation of regional nodal metastases would be a
marker of the high-risk subset9; however, surgical
staging of the nodes is limited in the context of a
conventional completion mastectomy. We hypothe-
sized that lymphatic mapping and sentinel lymph
node biopsy in patients with locally recurrent breast
cancer would facilitate the ability to surgically stage
their regional lymphatic drainage patterns. This study
was designed to evaluate the clinicopathologic fea-
tures, including correlations with lymphatic mapping
and lymphoscintigraphy findings, in a series of breast
cancer patients treated for local recurrence.
METHODS
The conduct of this retrospective review was ap-
proved by the Institutional Review Board for the
University of Michigan. The medical records were
reviewed for all breast cancer patients undergoing
surgery at the University of Michigan Comprehensive
Cancer Center between January 2002 and December
2004 for a diagnosis of local recurrence after prior
breast-conservation therapy. Clinical and pathologic
characteristics of the initial primary cancer diagnosis
and the recurrence were evaluated.
The Surgical Breast Section at the University of
Michigan has used lymphatic mapping and sentinel
lymph node biopsy in the management of primary
breast cancer since 1999, and in 2002 we expanded its
application to include patients undergoing comple-
tion mastectomy for locally recurrent breast cancer.
Because lymphatic mapping would not be considered
the standard of care in surgically treating patients
with local recurrence from breast cancer, the final
decision regarding the use of this approach is left to
the discretion of the primary surgeon and the patient.
Our mapping procedure has been internally validated
for accuracy and is standardized as follows: a su-
bareolar injection of 4 mCi 99mTc-labeled sulfur col-
loid (unfiltered) is administered 18 to 24 hours before
the scheduled cancer surgery. Preoperative lympho-
scintigraphy is performed on the morning of surgery.
The primary surgeon injects 3 to 5 mL of blue dye
(Lymphazurin 1% isosulfan blue dye, U.S. Surgical
Corp., Norwalk, CT) into the breast peritumorally
and into the dermis overlying the tumor 5 minutes
before making the skin incision. The sentinel nodes
are identified during surgery by visual inspection,
palpation, and use of the handheld gamma detector.
The sentinel nodes are evaluated pathologically for
evidence of metastases by serial sectioning with
hematoxylin and eosin staining.
Lymph nodes retrieved in the surgical specimens of
patients with local recurrence were evaluated on the
basis of whether lymphatic mapping was performed.
Patterns of primary lymphatic drainage (as docu-
mented by preoperative lymphoscintigraphy) in the
locally recurrent breast cancer cases were compared
with patterns observed in our institution for a rep-
resentative sample of control patients who underwent
sentinel node biopsy for primary breast cancer within
the same time period. The cases and controls for this
study were identified via the University of Michigan
Surgical Breast Section procedure records. Compar-
ison of the drainage patterns reported by lympho-
scintigraphy was evaluated by v2 statistical testing.
RESULTS
Fourteen patients undergoing completion mastec-
tomy for locally recurrent breast cancer were evalu-
ated. The clinicopathologic profile for these patients
is shown in Table 1. The median age for these
patients at the time of the initial breast cancer diag-
nosis was 50 years, and the mean time to local
recurrence from the date of primary disease detection
was 43 months (range, 14–170 months). The median
age at the time of local recurrence was 54 years
(range, 34–70 years). Ten of these patients (71%) had
lymphatic mapping and sentinel lymph node biopsy
performed concomitantly with their completion
mastectomy. Lymphatic mapping was performed
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with blue dye as the only mapping agent in one case
and with dual agents (blue dye and isotope) in the
remaining nine cases. Four patients underwent
completion mastectomy alone, with no lymphatic
mapping.
Lymphatic mapping and surgical pathology find-
ings from these cases of local recurrence are listed in
Table 2. Among the four cases managed by com-
pletion mastectomy alone, only one patient had
lymph node tissue identified in the surgical speci-
men, and this incidentally detected lymph node
within the axillary tail of the breast was a metastatic
lesion. A sentinel node was identified in 9 of the 10
mastectomy cases performed with lymphatic map-
ping (sentinel identification rate, 90%), and none of
these nodes was metastatic. For the nine cases that
included dual-agent lymphatic mapping, radioactive
sentinel lymph nodes were identified in eight (89%).
One patient had no radioisotope uptake on preop-
erative lymphoscintigraphy, and no uptake was de-
tected during surgery, either; this patient did have a
single blue-stained sentinel node in the ipsilateral
axilla. It is interesting to note that this patient had
undergone prior sentinel lymph node biopsy (with-
out completion ALND) at the time of her initial
breast cancer operation. The one patient who
underwent lymphatic mapping with blue dye only
had a single blue node identified in the ipsilateral
axilla. The case of sentinel node nonidentification
occurred in a patient with lymphoscintigraphy re-
sults that revealed contralateral axillary and internal
mammary drainage; however, it had been decided
before surgery to attempt retrieval only of ipsilateral
axillary nodes.
TABLE 1. Clinicopathologic features of the study patient population undergoing treatment for locally recurrent breast cancer
Patient no.
Age at primary





1 42 T1N1 L/ALND/XRT 132 1.5
2 67 DCIS L/XRT 27 .3
3 33 T1N1 L/ALND/XRT 14 3.0
4 40 T2N0 L/ALND/XRT 162 1.2
5 40 T1N0 L/ALND/XRT 170 .7
6 44 DCIS L/XRT 68 .3
7 53 T1N0 L/ALND/XRT 92 .6
8 56 T1N0 L/ALND/XRT 28 1.3
9 43 T1N0 L/SLNB/XRT 45 .6
10 55 T1N0 L/ALND/XRT 87 1.8
11 50 T2N1 L/ALND/XRT 24 5.5
12 62 T1N1 L/ALND/XRT 37 .7
13 57 T2N1 L/ALND/XRT 23 1.3
14 46 T1N0 L/SLNB/XRT 36 .5
CA, cancer; Dx, diagnosis; L, lumpectomy; ALND, axillary lymph node dissection; XRT, breast radiation; SLNB, sentinel lymph node
biopsy.















1 ALND X X
2 None X







10 ALND X X
ALND, axillary lymph node dissection; SLNB, sentinel lymph node biopsy.
a Four additional patients with local recurrence from this series were managed by completion mastectomy without lymphatic mapping.
b Patient numbers correlate with patient numbers from Table 1.
c Ipsilateral axillary sentinel lymph node identified by blue dye mapping.
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Eight of the sentinel node specimens identified by
isotope mapping were located in the contralateral
axillae; three of these patients also had ipsilateral
internal mammary chain sentinel nodes. Only one
patient had ipsilateral axillary sentinel lymph node
location. This patient had been previously treated for
ductal carcinoma-in-situ by lumpectomy and breast
radiation, but not by ALND.
The lymphatic drainage patterns for these cases of
local recurrence were also compared with the patterns
observed on preoperative lymphoscintigraphy per-
formed on a sample of 117 patients with primary
breast cancer treated within the same time interval as
the study population of patients with locally recur-
rent breast cancer. In the primary breast cancer pa-
tients, extra-axillary sentinel nodes were detected in
17 cases (14.5%): supraclavicular in 12; internal
mammary in 4, and internal mammary as well as
supraclavicular in 1. Concomitant ipsilateral axillary
drainage was detected in all 12 of these cases. The
difference in the rate of nonipsilateral axillary drain-
age between the primary breast cancer and locally
recurrent breast cancers, as documented by lympho-
scintigraphy, was statistically significant (14.5% vs.
66.7%; P = .001).
The median number of lymph nodes retrieved for
pathology evaluation in the local recurrence cases
managed by mastectomy only was 1 (range, 0–1),
versus 3 (range, 1–6) in the cases in which lymphatic
mapping and sentinel node dissection were per-
formed. The median number of sentinel nodes
retrieved among the patients who underwent sentinel
node dissection for early-stage primary breast cancer
was also 3.
DISCUSSION
Advances in breast cancer management, including
an expanded armamentarium of hormonally active
agents, chemotherapy, and novel targeted therapies,
have resulted in improved disease-related outcomes.
Furthermore, several trends in cancer surveillance
and treatment are likely to improve eligibility for
breast conservation therapy15:
1. Increasing incidence rates of breast cancer among
young women.
2. Earlier detection of breast cancer via screening
mammography, with more tumors detected at
sizes that are amenable to lumpectomy.
3. Expanded applications for neoadjuvant chemo-
therapy, with tumor downstaging and increased
breast-conservation therapy eligibility.
As the subset of conservatively treated breast
cancer patients enlarges, in conjunction with pro-
longed survival from the disease, we are likely to see
an increased number of women with either true in-
breast recurrences or new primary tumors in the
previously treated breast. The survival equivalence of
breast-conserving approaches compared with mas-
tectomy for stage-matched patients has been defini-
tively documented in multiple phase III clinical
trials.15–18 Although it has been definitively docu-
mented by multiple phase III clinical trials that
overall survival from breast cancer is equivalent for
stage-matched patients regardless of the choice for
lumpectomy versus mastectomy, it has also been
demonstrated that the development of a local recur-
rence is a marker of inherently more aggressive pri-
mary tumor biology.8 A local recurrence in the breast
is associated with a 3 to 5 times greater risk for
experiencing distant failure.8
Salvage mastectomy is currently the standard-of-
care management for patients who develop ipsilateral
cancerous lesions after previous treatment by lump-
ectomy and breast radiation, and approximately two
thirds of these patients will have prolonged disease-
free survival after the completion mastectomy.
Collectively, these patterns suggest that a subset of
in-breast recurrences are indicators of high-risk dis-
ease for which systemic adjuvant therapy would be
warranted; another subset (the majority) are cases
that will be adequately controlled by more extensive
local therapy alone. Identifying these disparate sub-
sets at the time of local recurrence has been an
ongoing challenge to clinicians involved in the mul-
tidisciplinary management of breast cancer since the
breast-conservation trials were initially completed.
Table 3 summarizes the results of selected studies
that have attempted to identify prognostic features
associated with outcome after completion mastec-
tomy for local recurrence. As shown, there are no
consistent characteristics to determine when systemic
therapy is indicated for a local recurrence. The
infrequency of nodal metastases in our series of local
recurrences (1 in 14) supports the concept that only a
minority of in-breast failures represent biologically
aggressive disease.
The disease-free interval, the size of an invasive
local recurrence, and the presence of nodal metasta-
ses at the time of recurrence have been correlated
with the need for systemic therapy to address distant
micrometastases. As with primary breast cancer, the
presence of regional nodal disease is an excellent
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surrogate marker for potential micrometastases in
distant organs. Most invasive breast cancer patients
treated >5 years ago, however, will have already
undergone an ipsilateral ALND. This results in an
anatomically altered axillary fat pad for resection in
cases in which completion mastectomy is required for
management of a local recurrence. It is likely that the
primary lymphatic drainage of the breast will have
been rerouted as a consequence of the previous ax-
illary surgery, and breast radiation may alter intra-
mammary lymphatic patterns as well.
The conventional salvage mastectomy performed
for locally recurrent breast cancer is therefore inad-
equate for obtaining information regarding the re-
gional extent of disease. Foci of occult metastasis in
the ipsilateral axilla will be more difficult to identify,
and lymphatic drainage to the alternative nodal ba-
sins will be overlooked completely. The technology of
lymphatic mapping and sentinel lymph node biopsy
for breast cancer offers a unique opportunity to ex-
plore and restage the patient who experiences a local
recurrence from breast cancer. Dominant lymphatic
drainage to extra-axillary nodal basins, such as the
internal mammary chain, the supraclavicular fossa,
and even the contralateral axilla, is identified by
lymphatic mapping and preoperative lymphoscintig-
raphy in approximately 10% of patients who undergo
surgical treatment for primary breast cancer.
This study confirmed our a priori hypothesis that
primary lymphatic drainage patterns in the breast are
different after an ALND with or without breast irra-
diation. Lymphatic mapping with radioisotope injec-
tion and lymphoscintigraphy in our subset of patients
who underwent mastectomy for locally recurrent
breast cancer revealed drainage to extra-axillary sen-
tinel lymph nodes in nearly all cases. Because regional
metastatic spread of disease will similarly be affected,
this information can direct the surgical staging plan,
and systemic therapy recommendations can take into
account the presence versus the absence of disease in
any aberrantly located sentinel nodes. Figure 1 dem-
onstrates the lymphoscintigraphy results in a patient
who underwent completion mastectomy after prior
ALND and had primary lymphatic drainage detected
in the internal mammary and contralateral axilla. We
included four cases of salvage mastectomy alone
(without lymphatic mapping) performed for local
recurrence during the same time frame as our study
patients, and this sample demonstrated the typical
scenario of few or no lymph nodes retrieved with this
‘‘conventional’’ approach. Only three of the patients
in our series received chemotherapy for their local
recurrence—the one patient with nodal failure, an-
other patient with a 5-cm invasive recurrence, and the
patient whose mapping was unsuccessful in identify-
ing any sentinel lymph nodes. Had any of the other
patients been found to harbor metastases in their
aberrantly located nodes, it is likely that they would
have received systemic therapy as well.
Patients with local recurrence after prior lumpec-
tomy and limited axillary surgery (e.g., sentinel
lymph node biopsy) are also likely to benefit from
TABLE 3. Selected studies of prognostic features in patients with locally recurrent breast cancer
Study No. of local recurrences 5-y overall survival (%) Adverse prognostic featuresa
Kurtz, 19897 178 69 DFI <5 y
Stotter, 19892 55 63 Local recurrence >5 cm; unresectable nodes at time of recurrence
Cajucom, 19934 25 65 Local recurrence >2 cm; ‡4 metastatic nodes at time of recurrence
Voogd, 19993 266 61 Local recurrence >1 cm; nodal status of the primary tumor
Dalberg, 200311 307 68 DFI <3 y; nodal status of the primary tumor
DFI, disease-free interval (time to local recurrence).
a Features associated with poor outcome after completion mastectomy.
FIG. 1. Preoperative lymphoscintig-
raphy in a patient with local recur-
rence undergoing completion
mastectomy, revealing drainage to the
contralateral axilla and ipsilateral in-
ternal mammary nodal chains. INJ,
periareolar injection sites.
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lymphatic mapping and sentinel node biopsy at the
time of their in-breast relapse. There are few data
reported thus far on the feasibility of repeat mapping
procedures in breast cancer patients. The surgical
breast group at Memorial Sloan-Kettering Cancer
Institute reported on results from ‘‘reoperative’’ sen-
tinel lymph node biopsy in a series of 32 patients who
had undergone prior axillary surgery for both benign
and malignant conditions, and they had an identifi-
cation rate of 75%.19 Our group has looked at the
feasibility of sequential sentinel node biopsy proce-
dures in neoadjuvant chemotherapy patients before
and after the induction systemic therapy, with iden-
tification rates of 92%.20 This study included only one
patient whose initial breast cancer had been staged by
prior axillary sentinel lymph node biopsy. This pa-
tient had another axillary sentinel node detected by
blue dye mapping at the time of her mastectomy for
local recurrence. Even in cases of local recurrence
after breast conservation with no prior axillary
operation, lymphatic mapping may improve staging
of the relapse, because the breast radiation may have
altered the primary lymphatic drainage patterns.
In summary, our study demonstrates that lym-
phatic mapping for locally recurrent breast cancer is
feasible. Lymphatic mapping performed with radio-
isotope and lymphoscintigraphy is likely to identify
sentinel nodes located in the contralateral axilla or
the internal mammary chain. Blue dye in addition to
isotope mapping increases the sentinel node identifi-
cation rate. We believe that the nodal staging of
patients who experience a local recurrence after
breast-conservation therapy can potentially contrib-
ute meaningful information regarding the underlying
tumor biology and that these findings can be incor-
porated into recommendations for systemic therapy.
Our findings require validation in other breast cancer
datasets so that their prognostic value can be defined.
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